CHEREZ POUNCEY: Open Payments
NPI 1407324700 · EUSTIS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,249 in 34 payments from 15 companies in 2025. Trend: 2023 $289 · 2024 $799 · 2025 $1,249
Food & beverage: $1,249
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $232 |
| Alexion Pharmaceuticals, Inc. | 5 | $193 |
| Alnylam Pharmaceuticals Inc. | 2 | $165 |
| Genentech USA, Inc. | 1 | $146 |
| Amgen Inc. | 3 | $144 |
| TG Therapeutics, Inc. | 1 | $130 |
| ABBVIE INC. | 3 | $61 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $27 |
| TerSera Therapeutics LLC | 1 | $24 |
Products named: HYQVIA, AMVUTTRA, ULTOMIRIS, Ocrevus, BRIUMVI, SKYRIZI, UPLIZNA, NUCALA.
Industry payments across FL — which companies pay providers there.
